GLPwatch
Papers (9189)
Page 135 of 154, ranked by citation count.
- In brief: Semaglutide (Wegovy) for weight loss in children.
- Semaglutide (Ozempic) for weight loss.
- Type 2 diabetes and cardiovascular disease: A metabolic overview of recent clinical trials.
- Glycaemic control, body weight, and safety of tirzepatide versus dulaglutide by baseline glycated haemoglobin level in Japanese patients with type 2 diabetes: A subgroup analysis of the SURPASS J-mono study.
- Anti-CGRP monoclonal antibodies counteract establishment of food aversive memories and chemotherapy-induced anorexia and weight loss.
- Clinical experience with liraglutide.
- [Glucagon-like peptide-1 analogues: effects on body weight and glycemia].
- Two new GLP-1 receptor agonists for diabetes.
- Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon.
- GLP-1 receptor agonists and GIP/GLP-1 co-agonists in the treatment of obesity in adolescents and the elderly.
- Tirzepatide counteracts brown adipose tissue whitening, inflammation, and mitochondrial dysfunction in estrogen-deficient obese diabetic mice.
- Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial.
- Response To "Superior Cerebrovascular Outcomes with Tirzepatide Versus Semaglutide: A Call for Cautious Interpretation of Observational Data".
- GLP-1 Signalling as a Therapeutic Avenue in Parkinson's Disease: A Comprehensive Review.
- Ethical Issues Related to the Use of GLP-1 Receptor Agonists Such as Ozempic and Mounjaro: Impact on Individuals and Society at Large.
- GLP-1 Receptor Agonist Medications for Obesity and Type 2 Diabetes Treatment: A Rapid Review of Changes in Eating Behaviors and Eating Disorder Risk.
- Effect of switching from dulaglutide to tirzepatide on blood glucose and renal function.
- Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide.
- Who Wins the Battle Against Obesity? A Network Meta-Analysis Comparing Tirzepatide and Semaglutide.
- Semaglutide in weight management.
- Dipeptidyl peptidase-4 inhibitors do not alter GH/IGF-I axis in adult diabetic patients.
- Exenatide for once-weekly administration.
- Incretin physiology and its role in type 2 diabetes mellitus.
- Knowledge, attitude and practice toward liraglutide and semaglutide among endocrinology medical staff.
- [The GLP-1 analogue battle: effects of semaglutide 0,5 mg/weekly versus liraglutide 3 mg/daily on anthropometric parameters after 3 months in a real world-scenario].
- Plastic Surgery in the Ozempidemic: Considerations for the Timing of Body Contouring Surgery in Patients with Semaglutide-Associated Weight Loss.
- New developments in GLP-1 agonist therapy for gestational diabetes: Systematic review on liraglutide, semaglutide, and exenatide from ClinicalTrials.gov.
- Treatment of obesity with GLP-1 receptor agonist after bariatric surgery: Real-world evidence.
- Tirzepatide as a Potential Disease-Modifying Therapy in Lipedema: A Narrative Review on Bridging Metabolism, Inflammation, and Fibrosis.
- The cost-utility and budget impact analyses of Tirzepatide versus once-weekly Semaglutide as add-on therapy to metformin in patients with type 2 diabetes mellitus in China.
- Semaglutide versus tirzepatide for people with type 2 diabetes: cost of glycemic control in Austria, the Netherlands, Lithuania, and the United Arab Emirates.
- Tirzepatide associated autoimmune encephalitis: A case report.
- [The glucagon-like peptide-1 receptor-agonist semaglutide].
- Effects of Semaglutide and Tirzepatide on Recurrent Weight Gain After Bariatric Surgery: A Systematic Review and Meta-analysis.
- Effectiveness and safety of once-weekly subcutaneous semaglutide versus other glucose-lowering agents in real-world patients with type 2 diabetes: A retrospective, observational post-marketing study.
- Comment on: "Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 trials".
- Growth hormone treatment does not augment the anti-diabetic effects of liraglutide in UCD-T2DM rats.
- Brain activity associated with breakthrough food preoccupation in an individual on tirzepatide.
- Efficacy, Safety, and Future of GLP-1 Receptor Agonists: A Systematic Literature Review and Meta-Analysis.
- Weight and body composition outcomes with liraglutide in individuals with well-treated hypothyroidism: A retrospective case-control study.
- Effects of liraglutide on the testis of rats with experimental diabetes and ischemia-reperfusion injury.
- The Cardiovascular Outcomes Between Liraglutide and Dulaglutide Among Different Chronic Kidney Disease Stages in Patients With Type 2 Diabetes.
- The Sit Less, Interact and Move More (SLIMM-2) Trial: Protocol for a randomized control trial of a sedentary behavior intervention, resistance training and semaglutide on sedentary behavior in persons with chronic kidney disease.
- Methodological concerns with the meta-analysis comparing insulin degludec/liraglutide and insulin glargine/lixisenatide.
- GLP-1 agonist-associated presentations to unscheduled care: An opportunistic pilot study.
- Semaglutide vs tirzepatide in patients with obesity and HFpEF: a report from a global federated research network.
- The short-term cost-effectiveness of once-weekly semaglutide versus once-weekly dulaglutide for the treatment of type 2 diabetes mellitus in Colombian adults.
- Exenatide for diagnosing endogenous hyperinsulinemic hypoglycemia: a randomized placebo-controlled, double-blind, cross-over proof-of-principle study.
- Tirzepatide-induced weight loss and obstructive sleep apnea improvement in an adult with type 2 diabetes: A case report.
- Once-weekly glucagon-like peptide 1 receptor agonists.
- Multi-database pharmacovigilance assessment of GLP-1 receptor agonist-related ophthalmic risks using advanced signal detection in FAERS and vigibase.
- Integrating incretin-based therapy into type 2 diabetes management.
- [Impact on weight loss and body composition of a food education intervention associated with Liraglutide treatment to address obesity].
- Impact of chemical structure, lipidation and formulation on luminal stability and intestinal absorption of GLP-1 analogues.
- Impact of semaglutide use on glycemic and metabolic profile in adults with type 1 diabetes having overweight or obesity: A systematic review and meta-analysis.
- CCK Response Deficiency in Synphilin-1 Transgenic Mice.
- [Natriuretic effect of exenatide: high efficacy and site of action].
- Semaglutide in weight management - Author's reply.
- 2017 New Drug Update.
- GLP-1 receptor agonist exendin-4 suppresses food intake by inhibiting hindbrain orexigenic NPY neurons.